

REFERENCIAS

1. Rosas M, Pastelín G, Vargas-Alarcón G, et al. Guías clínicas para la detección, prevención y tratamiento de hipertensión arterial sistémica en México. Archivos de Cardiología de México; 2008;78,S2: 5-57.
2. Mire DE, Silfani TN, Pugsley MK, et al. A review of the Structural and Functional Features of Olmesartan Medoxomil, An Angiotensin Receptor Blocker. J Cardiovasc PharmacolTM 2005;46:585-593.
3. Smith DH, Cramer MJ, Neutel JM, et al. Comparison of telmisartan versus losartan: metaanalysis of titration-to-response studies. Blood Pressure Monitoring 2003, Vol. 8 No. 3;111-117.
4. Elmfeldt D, Olofsson B, Meredith P. The Relationships Between Dose and Antihypertensive Effect of Four AT 1 -receptor Blockers. Differences in Potency and Efficacy. Blood Pressure 2002; 11:293-301.
5. Lewington S, et al. Prospective Studies Collaboration*. Age-specific relevance of usual blood pressure to vascular mortality: a metaanalysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13.
6. Montzouris D. Comparative study on candesartan cilexetil and Nebivolol in arterial hypertension control. Journal of Hypertension 2003;21(suppl 4):S330.
7. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665.
8. Tamargo J; Caballero R; Gómez R; Núñez L; Vaquero M; Delpón E. Características farmacológicas de los ARA-II. ¿Son todos iguales? Rev Esp. Cardiol Supl. 2006;6:10C-24C.
9. Uehara G. and Takeda H. Relative effects of Telmisartan, Candesartan and Losartan on Alleviating Arterial Stiffness in patients with Hypertension complicated by diabetes mellitus: an Evaluation using the Cardio-Ankle Vascular Index (CAVI). The Journal of international medical research 2008; 36: 1094-1102.
10. Lacourcière Y, Asmar R. A comparison of the Efficacy and Duration of Action of Candesartan Cilexetil and Losartan as Assessed by Clinic and Ambulatory Blood Pressure After a Missed Dose, in Truly Hypertensive Patients. A Placebo-Controlled, Forced Titration Study. Am J Hypertension 1999;12:1181-1187.
11. Khawaja Z, Wilcox CS. An overview of candesartan in clinical practice. Expert Rev Cardiovasc Ther. 2011 Aug;9(8):975-82.
12. Julius S, Nesbitt S, Egan BM et al. Feasibility of Treating Prehypertension with an Angiotensin-Receptor Blocker. N Engl J Med 2006;354:1685-97.13. Estudios clínicos clave en HTA. AstraZeneca.

13. Estudios clínicos clave en HTA. AstraZeneca.
14. Barrios V, Escobar C, Calderón A, et al. Regression of left ventricular hypertrophy by a candesartan-based regimen in clinical practice. The VIPE study. *J Renin Angiotensin Aldosterone Syst.* 2006 Dec;7(4):236-42.
15. Ogihara T, Nakao K, Fukui T, et al. Effects of Candesartan Compared With Amlodipine in Hypertensive Patients With High Cardiovascular Risks. CASE-J Study. *Hypertension.* 2008;51:393-398.
16. Pfeffer M, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. *Lancet* 2003;362: 759 -66.
17. Sjølie AK, Klein R, Porta M, et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. *Lancet.* 2008;372(9647):1385-93.
18. Papademetriou V, Farsang C, Elmfeldt D, et al. Stroke Prevention With the Angiotensin II Type 1-Receptor Blocker Candesartan in Elderly Patients With Isolated Systolic Hypertension. The Study on Cognition and Prognosis in the Elderly (SCOPE). *Journal of the American College of Cardiology* 2004; 44(6):1175 -80.
19. Morgensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. *BMJ* 2000;321(7274):1440-4.
20. Cohn J, Tognoni G Effect of the Angiotensin Receptor Blocker Valsartan on Morbidity and Mortality in Heart Failure: the Valsartan Heart Failure Trial (Val-HeFT). *Circulation.* 2000; 102: 2672.
21. Burgess E, Muirhead N, de Cotret PR, et al. Supramaximal Dose of Candesartan in Proteinuric Renal Disease. *J Am Soc Nephrol.* 2009;20(4):893-900.
22. Atacand® (Candesartan). Información para prescribir.
22. Ohman, Peter; Milon, Hugues; Valnes, Kolbjorn. Efficacy and tolerability of a combination tablet of candesartán Cilexetil and hydrochlorothiazide in insufficiently controlled primary hypertension - comparison with a combination of losartan and hydrochlorothiazide. *Blood pressure* 2000;9(4):214-22.